How TPP Helps Pharma
Pharma doesn't come up empty in TPP.
Market protection for the expensive class of biologic medicines has been the drug industry’s focus with the Trans-Pacific Partnership trade deal.
They didn’t win the 12 years of market exclusivity companies get in the U.S., but that doesn’t mean they didn’t get some valuable economic benefits in the deal which was finally made public late last week. And that’s not counting the 5-8 years of biologic protection in several TPP countries that used to have less or none.
Read the full article here.